Immunosuppressive regimens in lung transplant recipients

Drugs of Today

Volumn 40, Issue 12, 2004, Pages 1003-1012

  Bhorade, Sangeeta M ^a   Villanueva, Jaime ^a   Jordan, Ashby ^a   Garrity, Edward R ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIFUNGAL AGENT; AZATHIOPRINE; BASILIXIMAB; BROMOCRIPTINE; CALCIUM CHANNEL BLOCKING AGENT; CIMETIDINE; COLCHICINE; CORTICOSTEROID; CYCLOSPORIN A; DACLIZUMAB; DANAZOL; HYDROCORTISONE; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; METOCLOPRAMIDE; MONOCLONAL ANTIBODY CD3; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; OMEPRAZOLE; POLYCLONAL ANTIBODY; PREDNISOLONE; PREDNISONE; RAPAMYCIN; SULFINPYRAZONE; TACROLIMUS; TAMOXIFEN; THYMOCYTE ANTIBODY;

ABDOMINAL PAIN; BODY WEIGHT DISORDER; BONE MARROW SUPPRESSION; CATARACT; CLINICAL TRIAL; CUSHINGOID SYNDROME; DIABETES MELLITUS; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SUBSTITUTION; DYSPEPSIA; FEVER; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; GLUCOSE INTOLERANCE; GRAFT REJECTION; GROWTH RETARDATION; HEMATOLOGIC DISEASE; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRICHOSIS; HYPERURICEMIA; HYPOMAGNESEMIA; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL PNEUMONIA; KIDNEY DISEASE; LEUKOPENIA; LIVER DYSFUNCTION; LUNG INSUFFICIENCY; LUNG TRANSPLANTATION; MENTAL INSTABILITY; MOUTH ULCER; NAUSEA; NEUROTOXICITY; ORGAN TRANSPLANTATION; OSTEOPOROSIS; PEPTIC ULCER; RASH; REVIEW; SIDE EFFECT; SOLID ORGAN TRANSPLANTATION; THROMBOCYTOPENIA; WEIGHT GAIN; WOUND HEALING IMPAIRMENT;

DRUG ADMINISTRATION SCHEDULE; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LUNG TRANSPLANTATION; RANDOMIZED CONTROLLED TRIALS; TRANSPLANTATION;

EID: 12344299578     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2004.40.12.872575     Document Type: Review

References (50)

1. Wenger, R.M. Structures of cyclosporine and its metabolites. Transplant Proc 1990, 22: 1104-9.
2. Kahan, B.D. Cyclosporine. N Engl J Med 1989, 321: 1725-38.
3. Kovarik, J.M., Mueller, E.A., van Bree, J.B. et al. Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation. J Pharmaceut Sci 1994, 83: 444-6.
4. Keown, P., Landsberg, D., Halloran, P. et al. A randomized prospective multicenter pharmacoepidemiologic study of cyclosporine microemulstion in stable renal graft recipients. Report of the Canadian Neoral Renal Transplantation Study Group. Transplantation 1996, 62: 1744-52.
5. Goldstein, D.J., Zuech, N., Sehgal, V. et al. Cyclosporine-associated end stage nephropathy after cardiac transplantation. Transplantion 1997, 63: 664-8.
6. Kino, T., Hatanaka, H., Miyata, S. et al. FK-506, A novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiotics 1987, 40: 1256-65.
7. The US Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994, 331: 1110-5.
8. European FK506 Multicentre Liver Study Group. Randomized trial comparing tacrolimus (FK506) and cyclosporine in prevention of liver allograft rejection. Lancet 1994, 344: 423-8.
9. European Tacrolimus Multicenter Renal Study Group. Multicenter randomized trial comparing tacrolimus (FK-506) in the prevention of renal allograft rejection. Transplantation 1997, 64: 436-43.
10. Reichart, B., Meiser, B., Vigano, M. et al. European Multicenter Tacrolimus (FK506) Heart Pilot Study: One year results - European Tacrolimus Multicenter Heart Study Group. J Heart Lung Transplant 1998, 17: 775-81.
11. Keenan, R.J., Konishi, H., Kawai, A. et al. Clinical trial of tacrolimus versus cyclosporine in lung transplantation. Ann Thorac Surg 1995, 60: 580-5.
12. Keenan, R.J., Dauber, J.H., Iacono, A.T. et al. Long-term follow-up clinical trial of tacrolimus versus cyclosporine in lung transplantation. J Heart Lung Transplant 1998, 17: 59A.
13. Ross, D.J., Lewis, M.I., Kramer, M. et al. FK 506 'rescue' immunosuppression for obliterative bronchiolitis after lung transplantation. Chest 1997, 112: 1175-9.
14. Horning, N.R., Lynch, J.P., Patterson, G.A. et al. Tacrolimus rescue therapy for persistent or recurrent acute lung allograft rejection. J Heart Lung Transplant 1998, 17: 761-7.
15. Onsanger, D.R., Love, R.B., Jahania, M.S. et al. Efficacy of tacrolimus in the treatment of refractory rejection in heart and lung transplant recipients. J Heart Lung Transplant 1999, 18: 448-55.
16. Garrity, E.R., Hertz, M.I., Trulock, E.P. Suggested guidelines for the use of tacrolimus in lung transplant recipients. J Heart Lung Transplant 1999, 18: 175-6.
17. Ross, D.J., Waters, P.F., Levine, M. et al. Mycophenolate mofetil versus azathioprine Immunosuppressive regimens after lung transplantation: Preliminary experience. J Heart Lung Transplant 1998, 17: 768-74
18. Zuckermann, A., Klepetko, W., Birsan, T. et al. Comparison between mycophenolate mofetil and azathioprine based immunosuppressions in clinical lung transplantation. J Heart Lung Transplant 1999, 18: 423-40
19. Palmer, S.M., Baz, M.A., Sanders, L. et al. Results of a randomized, prospective, multicenter trial of mycophenalate mofetil versus azathioprine in the prevention of acute lung allograft rejection. Transplantation 2001, 71: 1772-6.
20. European Mycophenolate Mofetil Cooperative Study Group. Placebo controlled study of mycophenolate mofetil combined with cyclosporin and steroids for prevention of acute rejection. Lancet 1995, 345: 1321-5.
21. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996, 61:1029-37.
22. Sollinger, H.W. for the US Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995, 60: 225-32.
23. Schimmer, B.P., Parker, K.L. Adrenocorticotrophic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. In: Hardman, J.G., Goodman Gilman, A., Limbard, L.E. (Eds.). Goodman and Gilman's. The Pharmacological Basis of Therapeutics, 9th ed. McGraw Hill, New York 1996, 1459-85.
24. Briffa, N., Morris, R.E. New immunosuppressive regimens in lung transplantation. Eur Resp J 1997, 10: 2630-7.
25. Calne, R.Y., Collier, D.S., Lim, S. et al. Rapamycin for immunosuppression in organ allografting. Lancet 1989, 2: 227.
26. Morris, R., Meiser, B. Identification of a new pharmacologic action for an old compound. Med Sci Res 1989, 17: 609-10.
27. Cao, W., Mohacsi, P., Shorthouse, R., Pratt, R., Morris, R.E. Effects of rapamycin on growth factor-stimulated vascular smooth muscle cell DNA synthesis. Inhibition of basic fibroblast growth factor and platelet-derived growth factor action and antagonism of rapamycin by FK506. Transplantation 1995, 59: 390-5.
28. Gregory, C.R., Huang, X., Pratt, R.E. et al. Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement. Transplantation 1995, 59: 655-61.
29. Akselband, Y., Harding, M.W., Nelson, P.A. Rapamycin inhibits spontaneous and fibroblast growth factor beta-stimulated proliferation of endothelial cells and fibroblasts. Transplantation Proceedings 1991, 23: 2833-6.
30. Vu, M.D., Qi. S., Xu, D. et al. Tacrolimus (FK506) and sirolimus (rapamycin) in combination are not antagonistic but produce extended graft survival in cardiac transplantation in the rat. Transplantation 1997, 64: 1853-6.
31. Longoria, J., Roberts, R.F., Marboe, C.C., Stouch, B.C., Starnes, V.A., Barr, M.L. Sirolimus (rapamycin) potentiates cyclosporine in prevention of acute lung rejection. J Thoracic & Cardiovasc Surg 1999, 117: 714-8.
32. Cahill, B., Cromptom, T., Somerville, M. et al. Early experience with sirolimus in lung transplant recipients. J Heart Lung Transplant 2001, 20: 162(Abstr. 40).
33. Dunitz, J., Bolman, R.M., Park, S. et al. Sirolimus based immunosuppression in lung transplant recipients. Transplantation 1999, S103 (Abstr. 385).
34. Groth, G.G., Backman, L., Morales, J.M. et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation. 1999, 67: 1036-42.
35. Watson, C.J., Friend, P.J., Jamieson, N.V. et al. Sirolimus: A potent new immunosuppressant for liver transplantation. Transplantation 1999, 67: 505-9.
36. Groth, G.G., Brattstrom, C., Claesson, K., Backman, L. New trails in transplantation: How to exploit the potential of sirolimus in clinical transplantation. Transplant Proceed 1998, 30: 4064-5.
37. Carrier, M., White, M., Perrault, L.P. et al. A 10-year experience with intravenous thymoglobulin in induction of immunosuppression following heart transplantation. J Heart Lung Transplant 1999, 18: 1218-23.
38. Zuckermann, A.O., Grimm, M., Czerny, M. et al. Improved long-term results with thymoglobulin induction therapy after cardiac transplantation: A comparison of two different rabbit-antithymocyte globulines. Transplantation 2000, 69: 1890-8.
39. Brennan, D.C., Flavin, K., Lowell, J.A. et al. A randomized, double-blinded comparison of thymoglobulin versus ATGAM for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation 1999; 67: 1011-18.
40. Palmer, S.M., Miralles, A.P., Lawrence, C.M., Gaynor, J.W., Davis, R.D., Tapson, V.F. Rabbit antithymocyte globulin decreases acute rejection after lung transplantation: Results of a randomized, prospective study. Chest 1999, 116: 127-31.
41. Kohler, G., Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975, 256: 495.
42. Norman, D.J., Kahana, L., Stuart, F.P. et al. A randomized clinical trial of induction therapy with OKT3 in kidney transplantation. Transplant 1993, 55: 44-50.
43. Ross, D.J., Jordan, S., Nathan, S.D., Kass, R.M., Koerner, S.K. Delayed development of obliterative bronchiolitis syndrome with OKT3 after unilateral lung transplantation. Chest 1996, 109: 871-4.
44. Wain, J.C., Wright, C.D., Ryan, D.P., Zorb, S.L., Mathisen, D.J., Ginns, L.C. Induction immunosuppression for lung transplantation with OKT3. Ann Thorac Surg 1999, 67: 187-93.
45. Beniaminovitz, A., Itescu, S., Lietz, K. et al. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody. N Engl J Med 2000, 342: 613-9.
46. Nashan, B., Light, S., Hardie, I.R., Lin, A. Johnson, R., The Daclizumab Study Group. Reduction of acute renal allograft rejection by daclizumab. Transplantation 1999, 67: 110-5.
47. Soulillou, J.P., Cantarovich, D., Le Mauff, B. et al. Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts. NEJM 1991, 322: 1175-82.
48. Langrehr, J.M., Nussler, N.C., Neumann, U. et al. A prospective randomized trial comparing interleukin-2 receptor antibody versus antithymocyte globulin as part of a quadruple immunosuppressive induction therapy following orthotopic liver transplantation. Transplantation 1997, 63: 1172-81.
49. Brock, M.V., Borja, M.C., Ferber, L. et al. Induction therapy in lung transplantation: A prospective controlled clinical trial comparing OKT3, anti-thymocyte globulin, and daclizumab. J Heart Lung Transplant 2001, 20: 1282-90.
50. Garrity, E., Villanueva, J., Bhorade, S. et al. Low rate of acute lung allograft rejection after the use of daclizumab, an interleukin 2 receptor antibody. Transplantation 2001, 71: 773-7.